New hope for young bone cancer patients: can an added drug keep cancer away?
NCT ID NCT07321912
Summary
This study is testing if adding a drug called eflornithine (DFMO) to standard chemotherapy can help young people with Ewing sarcoma or osteosarcoma. It aims to see if this combination helps patients live longer without their cancer coming back. The trial will enroll about 406 participants in different groups based on their specific cancer type and stage.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.